ALLK vs. RVPH, MIST, CNTB, GNLX, DMAC, MCRB, ORMP, ACRS, BRNS, and CLSD
Should you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Reviva Pharmaceuticals (RVPH), Milestone Pharmaceuticals (MIST), Connect Biopharma (CNTB), Genelux (GNLX), DiaMedica Therapeutics (DMAC), Seres Therapeutics (MCRB), Oramed Pharmaceuticals (ORMP), Aclaris Therapeutics (ACRS), Barinthus Biotherapeutics (BRNS), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry.
Allakos (NASDAQ:ALLK) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
84.6% of Allakos shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 28.1% of Allakos shares are owned by company insiders. Comparatively, 31.8% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Allakos' return on equity of -80.23% beat Reviva Pharmaceuticals' return on equity.
Allakos currently has a consensus target price of $1.83, suggesting a potential upside of 79.74%. Reviva Pharmaceuticals has a consensus target price of $16.75, suggesting a potential upside of 460.20%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Allakos.
Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks.
Allakos received 165 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.89% of users gave Reviva Pharmaceuticals an outperform vote while only 59.34% of users gave Allakos an outperform vote.
Allakos has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.
In the previous week, Reviva Pharmaceuticals had 16 more articles in the media than Allakos. MarketBeat recorded 17 mentions for Reviva Pharmaceuticals and 1 mentions for Allakos. Allakos' average media sentiment score of 0.80 beat Reviva Pharmaceuticals' score of 0.28 indicating that Allakos is being referred to more favorably in the media.
Summary
Reviva Pharmaceuticals beats Allakos on 8 of the 15 factors compared between the two stocks.
Get Allakos News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
